biostudies-literatureBlesl AAustrian National BankAustrian Society of Gastroenterology and Hepatology9-19https://www.ebi.ac.uk/biostudies/studies/S-EPMC10769779biostudies-literatureUnknown30(1)<h4>Background</h4>Corticosteroids are used for induction of remission in patients with moderately to severely active ulcerative colitis. However, up to one-third of patients fail to this therapy. We investigated if fecal microbial composition or its metabolic capacity are associated with response to systemic corticosteroids.<h4>Methods</h4>In this prospective, multicenter study, patients with active ulcerative colitis (Lichtiger score ≥4) receiving systemic corticosteroids were eligible. Data were assessed and fecal samples collected before and after 4 weeks of treatment. Patients were divided into responders (decrease of Lichtiger Score ≥50%) and nonresponders. The fecal microbiome was assessed by the 16S rRNA gene marker and analyzed with QIIME 2. Microbial metabolic pathways were prediInflammatory bowel diseasesPrediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter Study.PMC10769779DFG RU504201ZX1915A17936Reinisch WWatschinger CKump PAden KMayer AHogenauer CTillinger WBinder LLudwiczek OKoch RReider SMoschen ABlesl AHaas TGrochenig HPNovacek GFurst SPrimas CReicht GWaschina SKutschera MWurm PHennlich BGorkiewicz GMiehsler WIlliasch CSteidl KSteiner PfalsePrediction of Response to Systemic Corticosteroids in Active UC by Microbial Composition-A Prospective Multicenter Study.<h4>Background</h4>Corticosteroids are used for induction of remission in patients with moderately to severely active ulcerative colitis. However, up to one-third of patients fail to this therapy. We investigated if fecal microbial composition or its metabolic capacity are associated with response to systemic corticosteroids.<h4>Methods</h4>In this prospective, multicenter study, patients with active ulcerative colitis (Lichtiger score ≥4) receiving systemic corticosteroids were eligible. Data were assessed and fecal samples collected before and after 4 weeks of treatment. Patients were divided into responders (decrease of Lichtiger Score ≥50%) and nonresponders. The fecal microbiome was assessed by the 16S rRNA gene marker and analyzed with QIIME 2. Microbial metabolic pathways were predi2024-01-01T00:00:00Z2024 Jan2026-06-01T21:51:14.804Z2024-12-04T10:29:21.583ZS-EPMC107697793746311810.1093/ibd/izad126